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Calcium-stimulated nuclear factor of activated T cells (NFAT) transcription activity at the interleukin-2
promoter is negatively regulated by cyclic AMP (cAMP). This effect of cAMP is mediated, in part, by protein
kinase A phosphorylation of NFAT. The mechanism of regulation involves the creation of a phosphorylation-
dependent binding site for 14-3-3. Decreased NFAT phosphorylation caused by the calcium-stimulated phos-
phatase calcineurin, or mutation of the PKA phosphorylation sites, disrupted 14-3-3 binding and increased
NFAT transcription activity. In contrast, NFAT phosphorylation caused by cAMP increased 14-3-3 binding and
reduced NFAT transcription activity. The regulated interaction between NFAT and 14-3-3 provides a mecha-
nism for the integration of calcium and cAMP signaling pathways.
Nuclear factor of activated T cells (NFAT) represents a
group of transcription factors that are implicated in the expres-
sion of Fas ligand and several cytokine genes, including those
encoding interleukin 2 (IL-2), IL-4, and tumor necrosis factor
alpha (18, 37, 47, 70). Four members of the NFAT group
(NFAT1/NFATC2/NFATp, NFAT2/NFATC1/NFATc, NFAT3,
and NFAT4/NFATC3) have been identified, and multiple al-
ternatively spliced isoforms have been described (25, 27, 45, 48,
56). Recent studies have confirmed that NFAT plays a critical
role in the expression of IL-2 and IL-4 by T cells (12, 18, 26,
77). However, roles for NFAT in other biological processes
have also been reported. For example, NFAT4 is required for
normal thymocyte development (57), NFATc participates in
heart valve development during embryogenesis (16, 61),
NFAT3 interacts with GATA4 and induces heart hypertrophy
(50), and NFAT activity controls gene expression in different
skeletal muscle fiber types (1, 11).
NFAT is present in the cytoplasm of resting cells (reviewed
in references 15 and 62). Upon T-cell activation, a sustained
increase in intracellular calcium activates the phosphatase cal-
cineurin (72). Calcineurin binds to a docking site in the NH2-
terminal region of NFAT (3), dephosphorylates phosphoserine
residues located in the NFAT homology domain, and induces
translocation of NFAT from the cytoplasm into the nucleus
(14, 29, 68). Recently, several protein kinases that phosphor-
ylate sites located in the NFAT homology domain have been
identified; these include glycogen synthase kinase 3, casein
kinase 1a, and c-Jun N-terminal kinase (5, 13, 83). The nuclear
localization of NFAT is therefore regulated by the opposing
actions of protein kinases and the phosphatase calcineurin.
NFAT was identified as the molecular target for cyclosporin
A (CsA), an immunosuppressive drug that has allowed impor-
tant advances in transplantation surgery (20, 66). CsA inhibits
calcineurin activity and thus blocks nuclear translocation of
NFAT, and consequently IL-2 secretion, by activated T cells
(14). In addition, stimuli that activate protein kinase A (PKA),
including prostaglandin E2, histamine, epinephrine, and im-
munosuppressive retroviral peptides, inhibit IL-2 gene expres-
sion (22, 31, 75). Conversely, suppression of cyclic AMP
(cAMP) signaling is required for T-cell activation (39). The
mechanism of inhibition appears to be mediated by the tran-
scriptional induction of phosphodiesterase 7 following T-cell
costimulation. Increased phosphodiesterase 7 expression is as-
sociated with decreased levels of cAMP and increased IL-2
production (39). Thus, the cAMP signaling pathway represents
a physiologically relevant regulatory mechanism that controls
IL-2 expression by T cells.
The mechanism by which cAMP regulates IL-2 gene expres-
sion has not been clearly defined. It is likely that the effects of
cAMP are mediated by activation of PKA since transfection
studies demonstrate that the expression of the PKA catalytic
subunit suppresses IL-2 promoter activity. Several potential
targets of PKA signaling have been identified. For example,
cAMP inhibits T-cell receptor tyrosine phosphorylation and
down-regulates c-Jun N-terminal kinase activity (28, 58). In
addition, several transcription factors, including inducible cy-
clic AMP early repressor (ICER) (6), NF-kB (54), and NFAT,
have been identified as potential mediators of negative regu-
lation by cAMP (reviewed in reference 62). Interestingly, over-
expression of NFAT antagonizes the inhibitory effect of PKA
on IL-2 gene expression (73). Together, these actions of PKA
appear to inhibit IL-2 expression. Nevertheless, the mecha-
nisms that account for the effect of PKA remain unclear.
The purpose of this study was to examine the effect of PKA
on negative regulation of NFAT-mediated signal transduction.
We show that PKA phosphorylates NFAT and inhibits NFAT
transcription activity. Mutational analysis demonstrated that
these sites of NFAT phosphorylation by PKA are required for
regulation of NFAT transcription activity. NFAT phosphory-
lation by PKA creates binding sites for 14-3-3. We propose that
the PKA-regulated formation of NFAT–14-3-3 complexes
may, in part, mediate the effects of cAMP on NFAT transcrip-
tion activity.
MATERIALS AND METHODS
Cell culture and reagents. BHK fibroblasts, Jurkat T cells, and COS cells were
cultured in minimal essential medium, RPMI 1640, and Dulbecco modified
Eagle medium, respectively, supplemented with 10% fetal calf serum, 2 mM
L-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml) (Life Technol-
ogies Inc.). BHK and COS cells were transfected by using Lipofectamine (Life
Technologies). Ionomycin, phorbol myristate acetate, dibutyryl cAMP, cal-
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cineurin, calmodulin, 49,69-diamidino-2-phenylindole, H7, 3-isobutyl-1-methyl-
xanthine (IBMX), and monoclonal antibody M2 were obtained from Sigma.
Calcineurin inhibitory peptide and CsA were obtained from Calbiochem.
Expression vectors. Plasmids used for expression of Raf-1 (76), NFAT (27),
calcineurin (60), PKA catalytic subunit (46), and 14-3-3 (7, 41) have been de-
scribed elsewhere. Wild-type and mutated NFAT constructs were prepared by
PCR, sequenced, and cloned in pGEX-3X (Amersham Pharmacia Biotech Inc.)
and pCDNA3 (Invitrogen Inc.).
Luciferase reporter gene assays. An NFAT expression vector (0.3 mg) was
cotransfected with an NFAT-luciferase reporter plasmid (0.2 mg) and the control
plasmid pRSV b-galactosidase (0.2 mg) (13). The PKA catalytic subunit expres-
sion vector plasmid (0.1 mg) was cotransfected as indicated. Luciferase and
b-galactosidase activity were measured 48 h after transfection (13). The data are
presented as relative luciferase activity, calculated as the ratio of the activity of
luciferase to the activity of b-galactosidase (mean 6 standard deviation [n 5 3]).
Protein interaction assays. Cell extracts were prepared with Triton lysis buffer
(20 mM Tris [pH 7.4], 137 mM NaCl, 2 mM EDTA, 1% Triton X-100, 25 mM
b-glycerophosphate, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mg of leupeptin per ml). COS
cells were harvested 48 h after transfection. Jurkat cells (2 3 107) were treated
(20 min) without or with 2 mM ionomycin or with 500 mM dibutyryl cAMP plus
50 mM IBMX or 100 ng of CsA per ml. The cells were harvested in 400 ml of
two-times-concentrated Triton lysis buffer and centrifuged, and the lysate was
diluted by adding 400 ml of ice-cold water. Immunoprecipitation was performed
with either monoclonal antibody M2 or an NFATp antibody (Upstate Biotech-
nology Inc.). 14-3-3 in the immunoprecipitates was detected by immunoblot
analysis using a pan-14-3-3 antibody (SC-629; Santa Cruz Inc.).
Binding assays were performed by incubating cell extracts in Triton lysis buffer
with 5 mg of recombinant glutathione S-transferase (GST)–14-3-3 fusion protein
bound to 20 ml of glutathione-Sepharose beads (Amersham Pharmacia Biotech
Inc.) for 5 h at 4°C. After three washes with Triton lysis buffer, the bound
proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and electrotransferred to a polyvinylidene membrane
(Millipore). Immunoblot analysis was performed with the anti-NFATp antibody
67.1 (23) or an antibody to Raf-1 (76) and visualized by enhanced chemilumi-
nescence (Kirkegaard & Perry Laboratories).
In vitro translation. T7-coupled in vitro transcription-translation (Promega
Inc.) was performed in the presence of [35S]methionine (New England Nuclear
Inc.). Translated NFAT was used in binding assays, and bound NFAT was
visualized by autoradiography and quantitated by PhosphorImager (Molecular
Dynamics Inc.) analysis. Dephosphorylation of NFAT was performed in cal-
cineurin reaction buffer (50 mM HEPES [pH 7.4], 2 mM MnCl2, 0.5 mM EDTA,
15 mM 2-mercaptoethanol, 0.1 mg of bovine serum albumin per ml) in the
presence of purified calmodulin (250 U) and calcineurin (2.5 and 5 U). Cal-
cineurin inhibitory peptide (10 mg) was preincubated with calcineurin for 10 min
at 4°C before incubation with in vitro-translated NFAT protein.
Protein kinase assays. Phosphorylation of NFAT (1 mg) by purified PKA
catalytic subunit (4 U) was performed in kinase reaction buffer (25 mM HEPES
[pH 7.4], 25 mM b-glycerophosphate, 25 mM MgCl2, 2 mM dithiothreitol, 0.1
mM sodium vanadate) in the presence of 50 mM [g-32P]ATP.
Phosphopeptide analysis. COS cells were transfected with a Flag epitope-
tagged NFAT expression vector (6 mg) without and with a PKA expression vector
(2 mg) and incubated for 24 h. The transfected cells were then incubated with
[32P]phosphate (1 mCi/ml) for 5 h. The NFAT proteins were isolated by immu-
noprecipitation with anti-Flag monoclonal antibody M2. Immunoprecipitates
were separated by SDS-PAGE, electrotransferred to a polyvinylidene difluoride
membrane (Millipore), and visualized by autoradiography. The band containing
32P-labeled NFAT was excised from the membrane and digested with trypsin,
and the peptides obtained were examined by phosphopeptide mapping (8).
Phosphopeptide maps of NFAT phosphorylated in vivo were compared with
maps of NFAT phosphorylated by PKA in vitro.
Immunofluorescence analysis. BHK cells were transfected by using Lipo-
fectamine (Gibco-BRL) and an expression plasmid for Flag-tagged NFAT3 (0.3
mg), PKA (0.1 mg), or calcineurin (0.2 mg). NFAT was detected by immunoflu-
orescence analysis with anti-Flag monoclonal antibody M2 (13). The secondary
antibody was Texas red-conjugated anti-mouse immunoglobulin antibody (1:100;
Jackson Immunoresearch), and nuclei were visualized with 49,69-diamidino-2-
phenylindole.
RESULTS
Phosphorylation by PKA inhibits NFAT transcription activ-
ity. NFAT is implicated as an effector molecule that mediates
the negative regulatory action of PKA on IL-2 gene expression.
We tested whether NFAT is a substrate for PKA (Fig. 1A). In
vitro protein kinase assays using purified PKA catalytic subunit
demonstrated that NFAT3 is phosphorylated by PKA (Fig.
1A). Deletion analysis identified the NH2-terminal region of
NFAT3 as a substrate for PKA. Sequence analysis indicated
that there are several potential PKA phosphorylation sites in
this region: Ser-264, Ser-272, Ser-273, and Ser-289 (Fig. 1A).
These Ser residues are conserved in other members of the
NFAT group (Fig. 1A). We performed site-directed mutagen-
esis to replace these potential phosphorylation sites with Ala,
creating [Ala272,273,274] NFAT. Mutation at Ser-272, Ser-273,
and Ser-274 reduced PKA phosphorylation of NFAT3 (Fig.
1A). A similar reduction in PKA phosphorylation was caused
by mutation at Ser-289 (Fig. 1A). In contrast, replacement of
Ser-272, Ser-273, Ser-274, and Ser-289 with Ala eliminated
phosphorylation of NFAT3 by PKA (Fig. 1A). This observa-
tion indicated that Ser-264 was not phosphorylated by PKA.
Control experiments demonstrated that phosphorylation of
CREB by PKA in the same assay was not affected by these
NFAT3 mutations (data not shown). Together, these data
demonstrate that the PKA sites on NFAT3 are phosphorylated
in vitro.
Dephosphorylation of NFAT causes increased electrophoretic
mobility during SDS-PAGE (15, 62). We therefore examined
the electrophoretic mobility of wild-type and mutated
[Ala272,273,274,289] NFAT3. Immunoblot analysis demonstrated
that the mutated [Ala272,273,274,289] NFAT3 exhibited increased
electrophoretic mobility compared to wild-type NFAT3 (Fig.
1B). Activated calcineurin dephosphorylated both wild-type
and mutated [Ala272,273,274,289] NFAT3. Importantly, dephos-
phorylated wild-type and mutated [Ala272,273,274,289] NFAT3
showed similar electrophoretic mobilities (Fig. 1B). These data
suggest that the PKA sites contribute to the phosphorylation of
NFAT3 in vivo. To test this hypothesis directly, we examined
the in vivo phosphorylation of NFAT3 in cells labeled with
[32P]phosphate (Fig. 1C). Tryptic phosphopeptide mapping
demonstrated that coexpression of the PKA catalytic subunit
increased the number of phosphopeptides in wild-type NFAT3
(arrowheads in Fig. 1C). These PKA-dependent phosphopep-
tides were absent in maps of the mutated [Ala272,273,274,289]
NFAT3 that was not phosphorylated by PKA in vitro. To-
gether, these data establish that NFAT3 is phosphorylated in
vitro and in vivo by PKA.
Replacement of Ser-272, Ser-273, Ser-274, and Ser-289 of
NFAT3 eliminated phosphorylation by PKA in vitro (Fig. 1A).
Interestingly, Ser-272 and Ser-289 are conserved in other
members of the NFAT group of transcription factors (Fig. 1A).
We therefore postulated that Ser-272 and Ser-289 might rep-
resent the sites of NFAT3 phosphorylation by PKA. To test
this hypothesis, we tested the effect of the replacement of
Ser-272 and Ser-289 with Ala residues. Mutation at Ser-272
and Ser-289 was sufficient to prevent phosphorylation of
NFAT3 by PKA (Fig. 1D). These data indicate that Ser-272
and Ser-289 are phosphorylated by PKA. To test whether these
sites are phosphorylated in vivo, we examined the effect of
individual point mutations at each of these sites on NFAT3
phosphorylation (Fig. 1D). Phosphopeptide mapping demon-
strated that mutations at Ser-273 and Ser-274 did not cause
marked changes in NFAT phosphorylation in vivo. In contrast,
mutations at Ser-272 and Ser-289 caused the loss of phos-
phopeptides (arrowheads in Fig. 1D). These phosphopeptides
correspond to peptides observed in maps of NFAT3 phosphor-
ylated by PKA in vitro. Together, these data demonstrate that
Ser-272 and Ser-289 represent the major sites of NFAT3 phos-
phorylation by PKA in vivo and in vitro (Fig. 1D).
To test the effect of PKA phosphorylation on NFAT func-
tion, we examined the transcription activity of wild-type and
phosphorylation-defective NFAT3. Transcription activity was
measured by using an NFAT-luciferase reporter plasmid con-
taining three copies of an NFAT–AP-1 composite element
derived from the IL-2 promoter. Both wild-type and mutated
NFAT3 caused increased reporter gene expression (Fig. 1E).
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FIG. 1. Phosphorylation by PKA inhibits NFAT transcription activity. (A) Mutational analysis of NFAT3 phosphorylation by PKA. The primary sequence of the
NFAT homology domain of NFAT3 is compared with sequences of NFATp (NFAT1), NFATc (NFAT2), and NFAT4 (upper panel). Potential PKA phosphorylation
sites are highlighted with filled boxes. NLS-1 and the conserved SP box C are indicated. Recombinant NFAT3 (1 mg) was phosphorylated by purified PKA catalytic
subunit in the presence of [g-32P]ATP (middle panel; sizes are indicated in kilodaltons). Phosphorylated NFAT3 was detected by autoradiography and quantitated by
PhosphorImager analysis (lower panel). (B) Replacement of Ser272, Ser273, Ser274, and Ser289 with Ala increases the electrophoretic mobility of NFAT3 during
SDS-PAGE. Epitope-tagged wild-type and mutated [Ala272,273,274,289] NFAT3 were expressed in COS cells without (Control) and with activated calcineurin (DCN).
NFAT3 proteins were detected in immunoblot analysis by using monoclonal antibody M2. (C) NFAT3 is phosphorylated by PKA in vivo. Epitope-tagged wild-type and
mutated [Ala272,273,274,289] NFAT3 were expressed in COS cells without (Control) and with PKA. The cells were labeled with [32P]phosphate, and the NFAT3 proteins
were isolated by immunoprecipitation. The phosphorylation of NFAT3 was examined by tryptic phosphopeptide mapping. (D) PKA phosphorylates NFAT3 on Ser272
and Ser289 in vivo and in vitro. Recombinant NFAT3 (1 mg) was phosphorylated by purified PKA in the presence of [g-32P]ATP (upper left panel). The effect of
replacement of Ser272 and Ser289 with Ala was examined. The in vitro phosphorylated wild-type NFAT3 was examined by tryptic phosphopeptide mapping (upper right
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Treatment of the cells with dibutyryl cAMP or coexpression of
PKA catalytic subunit caused inhibition of transcription activ-
ity mediated by wild-type NFAT3 (Fig. 1F). In contrast, tran-
scription activity mediated by the mutated phosphorylation-
defective NFAT3 was not inhibited under these conditions
(Fig. 1F). These data suggest that PKA down-regulates NFAT
transcription activity by a mechanism that requires NFAT
phosphorylation.
FIG. 1—Continued.
panel). The phosphorylation of NFAT3 in vivo was also examined by phosphopeptide mapping of NFAT3 co-expressed with PKA in COS cells (middle and lower
panels). The effect of replacement of Ser272, Ser273, Ser274 or Ser289 with Ala was examined. Electrophoresis and chromatography are the horizontal and vertical
dimensions of the phosphopeptide maps, respectively. (E) Measurement of NFAT3 transcription activity in BHK cells. The effect of NFAT3 expression was examined
in cotransfection assays using an NFAT-luciferase reporter plasmid. The cells were treated without (Untreated) and with ionomycin (2 mM) and PMA (100 nM) (I1P)
for 16 h. The data are presented as relative luciferase activity (see Materials and Methods). (F) Mutation of the PKA phosphorylation sites blocks PKA-mediated
inhibition of NFAT3 transcription activity. Wild-type and mutated [Ala272,273,274,289] NFAT3 were expressed together with an NFAT-luciferase reporter plasmid in
BHK cells. The effect of treatment with dibutyryl cAMP (500 mM) and IBMX (50 mM) or coexpression without (Control) and with PKA on cells treated (24 h) with
ionomycin (2 mM) and PMA (100 nM) is presented. (G) Effect of PKA phosphorylation on the nuclear accumulation of NFAT3. The structure of NFAT3 is illustrated
schematically to show the serine-rich region (SRR), NLS-1 and NLS-2, NES, the conserved SP boxes (A, B, and C), and the Rel domain. Epitope-tagged NFAT3
proteins were expressed in BHK cells and detected by immunofluorescence microscopy using monoclonal antibody M2. The subcellular distribution of wild-type (WT)
and truncated NFAT3 (residues 1 to 580) was examined. The effect of mutation of the PKA phosphorylation sites and coexpression with PKA catalytic subunit or DCn
is presented. The percentage of cells with NFAT3 in nucleus (n 5 100) is presented, and images of representative cells are illustrated. The nuclei (blue) of transfected
cells expressing NFAT3 (red) are indicated with arrowheads.
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Phosphorylation is an important mechanism that regulates
the subcellular distribution of NFAT (15, 62). Two functionally
redundant nuclear localization sequences (NLS) in NFAT
have been identified (4, 44). These correspond to NFAT3
residues 268 to 270 (NLS-1) and 672 to 675 (NLS-2) (Fig. 1F).
Intramolecular interaction with phosphoserine residues lo-
cated in the NFAT NH2 terminus may control the function of
NLS-2 (5). However, the mechanism that regulates NLS-1 is
unclear. Interestingly, sites of PKA phosphorylation are lo-
cated adjacent to NLS-1. To test whether phosphorylation at
these sites alters NLS-1 function, we examined the effect of
PKA on the subcellular distribution of a truncated NFAT
molecule (residues 1 to 580) that contains NLS-1, but not
NLS-2, by immunofluorescence analysis (Fig. 1G). The trun-
cated NFAT3 molecule was found in the cytosol, and this
localization was not affected by PKA (Fig. 1G). Activated cal-
cineurin induced NFAT3 nuclear accumulation, which was
blocked by PKA (Fig. 1G). Replacement of the PKA phos-
phorylation sites with Ala residues eliminated the effect of
PKA to oppose calcineurin-stimulated nuclear accumulation
(Fig. 1G). These data indicate that PKA phosphorylation may
regulate the function of NLS-1.
Both NLS-1 and NLS-2 are implicated in the mechanism of
NFAT nuclear accumulation (4, 44). To test whether PKA was
able to regulate NFAT subcellular distribution we used full-
length NFAT3, which contains both NLS-1 and NLS-2. Immu-
nofluorescence analysis demonstrated that both wild-type and
mutated phosphorylation-defective NFAT3 were located in the
cytosol (Fig. 1G). Calcineurin-stimulated nuclear accumula-
tion was observed in experiments using both wild-type and
mutated phosphorylation-defective NFAT3 (Fig. 1G). No ef-
fect of PKA on the subcellular distribution of these NFAT3
molecules was observed (Fig. 1G). Together, these data indi-
cate that while PKA may regulate the function of NLS-1, PKA
signaling was not sufficient to alter the nuclear accumulation of
wild-type NFAT. This is probably because PKA does not reg-
ulate NLS-2. PKA can therefore inhibit NFAT transcription
activity independently of changes in the subcellular distribu-
tion of NFAT. Electrophoretic mobility shift assays indicated
that treatment with dibutyryl cAMP did not inhibit NFAT
DNA binding activity (data not shown). Thus, PKA may exert
a direct action on NFAT transcription activity. This effect of
PKA requires the sites of NFAT phosphorylation by PKA.
Phosphorylation-dependent interaction of NFAT with 14-
3-3. The sites of PKA phosphorylation are located within the
conserved NFAT homology region (Fig. 1A). This region is
postulated to form a complex subdomain upon phosphoryla-
tion that masks important NFAT regulatory elements, such as
NLS-1 (62). Formation of this subdomain may involve both
intra- and intermolecular interactions. To test whether PKA
phosphorylation altered intermolecular interactions, we used
NFAT as an affinity matrix to purify molecules that bind the
conserved NFAT homology region. Two proteins (30 and 60
kDa) were found to bind GST-NFAT3 but not GST (Fig. 2A).
The 60-kDa protein may correspond to the catalytic subunit of
calcineurin, which is known to bind to the NFAT homology
domain (3, 21). Indeed, immunoblot analysis confirmed that
calcineurin bound to GST-NFAT3 (data not shown). In con-
trast, the identity of the 30-kDa protein that bound NFAT3
was unclear. We suspected that this 30-kDa protein might be
14-3-3 because of the similar mass and the reported function of
14-3-3 as a phosphoprotein ligand (53). To test this hypothesis,
we performed immunoblot analysis using an antibody to 14-
3-3. These experiments demonstrated that the NH2-terminal
region of NFAT3 bound 14-3-3 (Fig. 2B).
NFAT was first characterized as a transcription factor in T
FIG. 2. NFAT interacts with 14-3-3. (A) Immobilized GST and GST-NFAT3
(residues 1 to 308) were incubated with extracts prepared from [35S]methionine-
labeled BHK cells. Bound proteins were separated by SDS-PAGE and detected
by autoradiography. (B) Recombinant GST and GST-NFAT3 (residues 1 to 308)
were phosphorylated by incubation with 1 mM ATP and purified PKA catalytic
subunit. Immobilized GST and GST-NFAT3 were incubated with extracts pre-
pared from Jurkat T cells. Bound 14-3-3 was detected by immunoblot (IB)
analysis. The GST and GST-NFAT3 fusion proteins were detected by staining
with Coomassie blue. (C) NFATp interacts with 14-3-3 in vivo. NFATp was
immunoprecipitated from Jurkat T cell extracts by using a rabbit antibody to
NFATp. Preimmune antibody was used as a control. 14-3-3 in the immunopre-
cipitates (IP) was detected by immunoblot (IB) analysis. (D) NFAT proteins
bind 14-3-3. NFAT3, NFAT4, NFATp and NFATc were expressed in COS cells.
NFATp was immunoprecipitated with an antibody to NFATp. Epitope-tagged
NFAT3, NFAT4, and NFATc were immunoprecipitated with the anti-Flag
monoclonal antibody (Ab) M2. 14-3-3 in the cells lysate and in the immunopre-
cipitates (IP) was detected by immunoblot (IB) analysis. Extracts prepared from
mock-transfected cells were used as a control. IgG, immunoglobulin G.
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cells (67). We therefore examined the interaction of endoge-
nous NFAT with 14-3-3 in T cells by coimmunoprecipitation
analysis. Jurkat T cells, which express predominantly the
NFATp isoform, were used for these assays. Immunoblot anal-
ysis demonstrated the presence of 14-3-3 in NFATp immuno-
precipitates (Fig. 2C). These data confirm the conclusion that
NFAT interacts with 14-3-3. Since the NH2-terminal region of
NFAT3 is conserved in the NFAT group of transcription fac-
tors, we also examined whether other members of the NFAT
group interacted with 14-3-3. Coimmunoprecipitation assays
demonstrated that 14-3-3 was detected in NFAT3, NFAT4,
NFATp, and NFATc immunoprecipitates (Fig. 2D). These
data indicate that interaction with 14-3-3 is a common property
of NFAT transcription factors.
PKA phosphorylation sites mediate the interaction of NFAT
with 14-3-3. To delineate the 14-3-3 binding site on NFAT, we
examined the interaction between various NFAT3 deletion
mutants and 14-3-3. Immunoblot analysis demonstrated simi-
lar levels of expression of the NFAT proteins (Fig. 3A). The
interaction between 14-3-3 and Raf-1 was not affected by the
various NFAT3 proteins (Fig. 3A). In contrast, deletion of
NFAT3 sequences caused marked changes in the binding of
NFAT3 to 14-3-3. Progressive COOH-terminal truncations of
NFAT3 demonstrated that the Rel domain was not required
for 14-3-3 binding. Further deletion to remove the NFAT
homology domain abolished the interaction with 14-3-3 (Fig.
3A). A fragment of the NFAT homology domain (NFAT3
residues 260 to 308) encompassed the major binding sites for
14-3-3. This region includes the sites of PKA phosphorylation
on NFAT3. We tested whether these phosphorylation sites are
relevant to the interaction of NFAT3 with 14-3-3. Coimmuno-
precipitation assays demonstrated that replacement of the
PKA phosphorylation sites with Ala markedly reduced the
coimmunoprecipitation of NFAT with 14-3-3 (Fig. 3B). These
data indicate that the PKA phosphorylation sites of NFAT3
are important for the interaction with 14-3-3. To quantitate the
contribution of the PKA phosphorylation sites to 14-3-3 bind-
ing, we examined the interaction of in vitro-translated [35S]me-
thionine-labeled NFAT3 to recombinant 14-3-3. We found
that wild-type NFAT3 bound to 14-3-3 approximately five
times as strongly as the mutated phosphorylation-defective
NFAT3 (Fig. 3C).
Phosphorylation of NFAT3 by PKA increased 14-3-3 bind-
ing in vitro (Fig. 2B). We therefore tested whether PKA in-
creased the binding of 14-3-3 to the mutated phosphorylation-
defective NFAT3. Coexpression of the PKA catalytic subunit
with wild-type NFAT3 increased 14-3-3 binding (Fig. 3D). Re-
placement of the PKA phosphorylation sites with Ala mark-
edly reduced 14-3-3 binding. Importantly, coexpression of the
PKA catalytic subunit did not increase 14-3-3 binding to the
phosphorylation-defective NFAT3. These data indicate that
the PKA phosphorylation sites on NFAT3 are required for the
PKA-stimulated interaction of NFAT3 with 14-3-3.
The binding of 14-3-3 can be phosphorylation dependent
(53, 79). We therefore examined whether phosphorylation con-
tributes to the interaction of NFAT with 14-3-3. NFAT3 pre-
pared by in vitro translation binds to 14-3-3 (Fig. 3C), suggest-
ing either that phosphorylation is not required or that the
translated NFAT3 is phosphorylated in the reticulocyte lysate.
To test the latter hypothesis, we investigated the effect of the
protein kinase inhibitor H7. Similar amounts of in vitro-trans-
lated NFAT3 were obtained in the absence and presence of H7
(Fig. 4A). However, the presence of H7 during in vitro trans-
lation caused a marked dose-dependent inhibition of NFAT3
binding to 14-3-3 (Fig. 4A). Similarly, treatment of in vitro-
translated NFAT3 with the phosphatase calcineurin caused
inhibition of NFAT3 binding to 14-3-3 (Fig. 4B). This effect of
calcineurin was blocked by a specific peptide inhibitor of cal-
cineurin activity. These data indicate that phosphorylation in-
creases NFAT interaction with 14-3-3. This conclusion was
confirmed by the observation that NFAT3 phosphorylation by
PKA increases binding to 14-3-3 both in vitro (Fig. 2A) and in
vivo (Fig. 3D).
To test whether 14-3-3 can mediate the inhibitory effect of
PKA phosphorylation on NFAT transcription activity, we in-
vestigated the effect of 14-3-3 overexpression. Since 14-3-3 is
an abundant cellular protein, a marked effect of ectopic 14-3-3
expression was not anticipated. However, the expression of
14-3-3t did cause a moderate (30%) reduction of the transcrip-
tion activity of wild-type NFAT3 but not the mutated phos-
phorylation defective NFAT3 that lacks PKA phosphorylation
sites (data not shown). These data are consistent with the
hypothesis that 14-3-3 binding might mediate the effect of PKA
on NFAT3 activity.
Regulation of NFAT binding to 14-3-3 by cAMP and cal-
cium. The ability of calcineurin to inhibit NFAT binding to
14-3-3 (Fig. 4B) suggests that calcium signaling may be a neg-
ative regulator of the interaction between NFAT and 14-3-3. In
contrast, PKA appears to be a positive regulator of NFAT
binding to 14-3-3 (Fig. 3D). The opposite effects of calcium
and cAMP on NFAT–14-3-3 complexes suggests that these
signaling pathways may have an antagonistic relationship in
vivo. To test this hypothesis, we examined the effect of calcium
and cAMP on the formation of endogenous NFATp–14-3-3
complexes in Jurkat T cells (Fig. 5A). Dibutytryl cAMP and
ionomycin were used to activate the PKA and calcium signal-
ing pathways, respectively. Coimmunoprecipitation assays
demonstrated that 14-3-3 coprecipitated with NFATp. Treat-
ment with ionomycin caused a marked reduction in NFATp–
14-3-3 complex formation. This effect of ionomycin was atten-
uated by treatment of the cells with dibutyryl cAMP (Fig. 5A).
Control experiments demonstrated that calcium and cAMP did
not affect the binding of Raf-1 to 14-3-3 (data not shown).
These data indicate that the cAMP signaling pathway can
antagonize the effect of calcium on NFATp–14-3-3 complex
formation.
The ability of ionomycin to inhibit NFATp–14-3-3 complex
formation was further examined in in vitro binding assays (Fig.
5B). Western blot analysis of extracts prepared from Jurkat T
cells demonstrated that ionomycin caused a marked increase in
the electrophoretic mobility of NFATp during SDS-PAGE.
This increased mobility has been reported to be caused by
calcineurin-mediated dephosphorylation (15, 62). Binding as-
says demonstrated that ionomycin treatment of Jurkat cells
inhibited the interaction of NFATp with 14-3-3 in vitro (Fig.
5B). This ability of ionomycin to increase the electrophoretic
mobility of NFATp and to inhibit binding to 14-3-3 was
blocked if the cells were incubated with the immunosuppres-
sive drug CsA, which inhibits the phosphatase activity of cal-
cineurin (Fig. 5B). The effect of ionomycin on NFATp–14-3-3
binding was also inhibited when the Jurkat T cells were incu-
bated with dibutyryl cAMP (Fig. 5C). Control experiments
demonstrated that dibutyryl cAMP and ionomycin did not alter
the interaction of 14-3-3 with the Raf-1 protein kinase. In
contrast to CsA, dibutyryl cAMP did not cause a marked de-
crease in NFATp electrophoretic mobility (Fig. 5C). These
data indicate that calcineurin inhibition does not mediate the
effect of dibutyryl cAMP. In contrast, these data are consistent
with the hypothesis that the phosphorylation of NFATp on a
limited number of sites accounts for the regulation of NFATp/
14-3-3 complex formation by the cAMP signaling pathway.
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DISCUSSION
14-3-3 was first described as a dimeric protein in the brain
(51). Subsequent studies demonstrated that 14-3-3 includes a
group of proteins that are highly conserved and ubiquitously
expressed (reviewed in references 2 and 63). The general
mechanism of action of 14-3-3 proteins appears to involve the
formation of complexes with target proteins. In some in-
stances, such complexes depend on the phosphorylation of the
14-3-3 binding partner. A general consensus sequence that
mediates phosphorylation-dependent binding to 14-3-3 has
been defined as RSXSpXP (53, 79). Nevertheless, other se-
quences containing phosphoserine have been shown to bind
14-3-3 (17, 36, 42, 81). Structural studies demonstrate the pres-
ence of a basic pocket within a conserved groove in 14-3-3 (40,
FIG. 3. Identification of the 14-3-3 binding site on NFAT. (A) Deletion analysis of NFAT3. The structure of NFAT3 is illustrated schematically. Flag-tagged NFAT3
proteins corresponding to residues 1 to 902, 1 to 580, 1 to 450, 1 to 365, 1 to 308, 1 to 260, 1 to 160, and 1 to 112 were expressed in COS cells and detected by immunoblot
analysis of cell lysates with monoclonal antibody M2. The binding of NFAT3 and Raf-1 to immobilized GST–14-3-3t was examined. Bound NFAT3 and Raf-1 were
detected by immunoblot analysis. (B) Replacement of Ser-272, Ser-273, Ser-274, and Ser-289 with Ala decreases NFAT3 binding to 14-3-3. Epitope-tagged wild-type
and mutated NFAT3 were expressed in COS cells and detected by immunoblot (IB) analysis of cell lysates with monoclonal antibody M2 (lower panel). The NFAT3
proteins were immunoprecipitated, and 14-3-3 present in the immunoprecipitates (IP) was detected by immunoblot analysis (upper panel; sizes are indicated in
kilodaltons. (C) Immobilized GST–14-3-3t was incubated with [35S]methionine-labeled wild-type and mutated [Ala272,273,274,289] NFAT3 prepared by in vitro
translation. Control experiments were performed with in vitro-translated luciferase. Proteins in the lysate and bound to the immobilized GST–14-3-3t were detected
by autoradiography and quantitated by PhosphorImager analysis. (D) Epitope-tagged wild-type and mutated [Ala272,273,274,289] NFAT3 were expressed in COS cells
without (Control) and with an expression vector for the PKA catalytic subunit (PKA). NFAT3 proteins were immunoprecipitated, and 14-3-3 present in the
immunoprecipitates (IP) was detected by immunoblot analysis (IB).
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78). This basic pocket was postulated to interact with phospho-
serine and to provide a specificity determinant for ligand bind-
ing by 14-3-3 (53). This hypothesis was confirmed by structural
studies of 14-3-3 bound to phosphopeptides (64, 79). However,
additional interactions between the phosphopeptide ligand
and residues present in the 14-3-3 groove also contribute to
binding specificity (64, 79).
Recent studies have established many functions for the in-
teraction of phosphoproteins with 14-3-3. Examples include
the observations that (i) 14-3-3 is required for the stabilization
of Raf-1 in its active conformation (19, 65, 71, 74), (ii) the
binding of 14-3-3 to Bad prevents interaction with Bcl-xL and
plays a key role in cell survival (80), (iii) the binding of 14-3-3
to Cdc25C is required for checkpoint control of the cell cycle
(59), and (iv) the binding of 14-3-3 to a Forkhead transcription
factor causes nuclear export and contributes to PKB-mediated
cell survival (9). Here we report the identification of the tran-
scription factor NFAT as a ligand for 14-3-3.
PKA and calcineurin regulate NFAT binding to 14-3-3.
Members of the NFAT group of transcription factors bind to
14-3-3. This binding is increased by PKA in vitro (Fig. 2B) and
in vivo (Fig. 3D). Conversely, the binding of NFAT to 14-3-3 is
inhibited by the phosphatase calcineurin in vitro (Fig. 4B) and
by calcium in vivo (Fig. 5). Replacement of the PKA phos-
phorylation sites with Ala blocked the inhibitory effect of PKA
on both NFAT transcription activity (Fig. 1) and the binding of
NFAT to 14-3-3 (Fig. 3). NFAT binding to 14-3-3 therefore
negatively correlates with NFAT transcription activity. Thus,
14-3-3 may function to suppress NFAT activity. This conclu-
sion is further supported by the observation that overexpres-
sion of 14-3-3 inhibits IL-2 gene expression (49). Interestingly,
PKA can induce 14-3-3 binding to NFAT in the presence of
activated calcineurin. Thus, cAMP signaling may act domi-
nantly with respect to signaling by calcineurin.
The sites of phosphorylation-dependent binding of 14-3-3 to
NFAT correspond to PKA sites located in the NH2-terminal
region of NFAT. These sites are located immediately adjacent
to NLS-1 of NFAT. It is therefore likely that the binding of
14-3-3 to NFAT would cause sequestration and inactivation of
NLS-1. This might cause redistribution of NFAT from the
nucleus to the cytoplasm and therefore inhibition of NFAT-
mediated transcription. The mechanism of nuclear export may
include sequestration of NLS-1, but it is also possible that
other processes are involved. Several possible mechanisms
have been established in previous studies. For example, the
yeast transcription factor Pho4 interacts in a phosphorylation-
dependent manner with the nuclear export receptor Msn5 (30,
35). A second example is provided by the observation that
14-3-3 proteins contain a conserved nuclear export signal
(NES) that may mediate CRM1-dependent translocation of
14-3-3 from the nucleus to the cytoplasm (9, 43). Thus, the
binding of 14-3-3 to NFAT may cause both the sequestration of
NLS-1 and the attachment of an NES. The NES of 14-3-3 may
augment the action of an NES present in the NFAT NH2-
terminal region that allows rapid CRM1-dependent nuclear
export (32, 33, 82).
Sequestration of NFAT NLS-1 by an NES-bearing 14-3-3
protein provides an extremely elegant mechanism by which
14-3-3 could regulate the subcellular localization of NFAT
transcription factors and thereby inhibit NFAT transcription
activity. Indeed, some evidence for this potential mechanism
was obtained. Studies of a truncated NFAT3 molecule (resi-
dues 1 to 580) that contains NLS-1 but not NLS-2 demon-
strated that calcineurin-induced nuclear translocation of
FIG. 4. Phosphorylation increases NFAT binding to 14-3-3. (A) [35S]methi-
onine-labeled NFAT3 was prepared by in vitro translation in the presence of
various concentrations of the protein kinase inhibitor H7 (0, 1, 10, 100, and 1,000
mM). The amount of NFAT3 in the lysate was detected after SDS-PAGE by
autoradiography (middle panel). The binding of NFAT3 to immobilized GST–
14-3-3t was examined by autoradiography (upper panel; sizes are indicated in
kilodalton) and was quantitated by PhosphorImager analysis (lower panel). (B)
Calcineurin inhibits NFAT3 binding to 14-3-3. [35S]methionine-labeled NFAT3
prepared by in vitro translation was incubated with calcineurin (2.5 and 5 U) and
calcineurin inhibitor peptide (10 mg). The amount of NFAT3 in the lysate was
detected after SDS-PAGE by autoradiography (middle panel). The binding of
NFAT3 to immobilized GST–14-3-3t was examined by autoradiography (upper
panel) and was quantitated by PhosphorImager analysis (lower panel).
FIG. 5. Calcium and cAMP regulate NFAT binding to 14-3-3. (A) Jurkat T
cells were incubated without and with dibutyryl cAMP (500 mM) plus IBMX (50
mM) for 20 min prior to treatment with ionomycin (2 mM, 20 min) or with
ionomycin plus PMA (100 nM, 20 min). NFATp proteins were immunoprecipi-
tated, and 14-3-3 present in the immunoprecipitates (IP) was detected by im-
munoblot analysis (IB). (B) Jurkat T cells were incubated without and with CsA
(100 ng/ml, 20 min) prior to treatment with ionomycin (2 mM, 20 min). Extracts
prepared from the Jurkat T cells were incubated with immobilized GST–14-3-3t.
Bound NFATp and Raf-1 were detected by immunoblot analysis. The presence
of equal amounts of NFATp in the lysates was confirmed by immunoblot anal-
ysis. The amount of GST–14-3-3t was confirmed by Coomassie blue staining. (C)
Jurkat T cells were incubated without and with dibutyryl cAMP (500 mM) plus
IBMX (50 mM) for 20 min prior to treatment with ionomycin (2 mM, 20 min).
Extracts prepared from the Jurkat T cells were incubated with immobilized
GST–14-3-3t. Bound NFATp and Raf-1 were detected by immunoblot analysis.
The presence of equal amounts of NFATp in the lysates was confirmed by
immunoblot analysis.
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NFAT was opposed by PKA and that this effect of PKA was
blocked by mutation of the NFAT phosphorylation sites. How-
ever, full-length NFAT3, which contains both NLS-1 and
NLS-2, exhibited calcineurin-induced nuclear translocation
that was not inhibited by PKA. These data indicate that while
14-3-3 has the potential to regulate the subcellular distribution
of NFAT, 14-3-3 by itself was insufficient to cause redistribu-
tion of nuclear NFAT to the cytoplasm. It is known that the
mode of 14-3-3 binding to phosphoproteins may influence the
function of the 14-3-3 NES (64). Thus, the difference observed
between the regulation of the full-length and truncated
NFAT3 molecules may reflect a difference in the mode of
14-3-3 binding to these phosphoproteins.
The observation that PKA does not alter the subcellular
distribution of full-length NFAT indicates that export of
NFAT from the nucleus does not account for the effect of PKA
to inhibit NFAT transcription activity at the IL-2 promoter.
Furthermore, we did not detect PKA-stimulated changes in
NFAT DNA binding activity. It is therefore possible that PKA
exerts a more direct effect on NFAT transcription activity and
that the formation of NFAT complexes with 14-3-3 contributes
to the altered function of NFAT following PKA activation. It
is likely that NFAT function is altered rather than simply
inhibited because while PKA inhibits IL-2 expression, PKA
causes increased expression of IL-4 and IL-5 (52). The mech-
anism by which PKA differentially regulates the NFAT-medi-
ated expression of IL-2 compared with IL-4 and IL-5 is un-
clear. It is possible that the NFAT complex with 14-3-3
contributes to this differential regulation. Evidence in favor of
this hypothesis was obtained from the observation that the
overexpression of 14-3-3 inhibits transcription activity at the
IL-2 promoter but increases transcription activity at the IL-4
promoter (49). The molecular basis for the differential effect of
14-3-3 on NFAT-mediated transcription is unclear. However,
we can speculate that NFAT complexes may differentially col-
laborate with other transcription factors that are relevant to
each promoter, including AP-1 at the IL-2 promoter (15, 62),
GATA-3 at the IL-5 promoter (69), and c-Maf or JunB at the
IL-4 promoter (24, 38).
Specificity of NFAT interaction with 14-3-3. Binding to 14-
3-3 was detected in coimmunoprecipitation assays using mem-
bers of the NFAT group, including NFATp, NFATc, NFAT3,
and NFAT4 (Fig. 2D). Interaction with 14-3-3 therefore ap-
pears to be a common property of NFAT transcription factors.
The 14-3-3 group of proteins includes seven members (2, 63).
Some of these 14-3-3 isoforms are expressed selectively in
certain tissues. For example, 14-3-3t is expressed in T cells
(55). It is possible that NFAT binds differentially to these
14-3-3 proteins. Preliminary studies designed to investigate
14-3-3 binding specificity indicated that the amount of NFATp
binding to 14-3-3t was approximately five times greater than
binding to 14-3-3z, while an equal amount of Raf-1 was found
to bind each 14-3-3 isoform (data not shown). Whether this
difference in binding activity in vitro is relevant in vivo is
unclear. Further studies will be required to resolve this ques-
tion. We note that previous studies have not established bio-
chemical differences in the ligand binding properties of 14-3-3
proteins (79). However, such differences are likely since genet-
ically nonredundant functions for specific 14-3-3 genes have
been identified in Drosophila (10, 34).
The specificity of NFAT interaction with 14-3-3 is deter-
mined, in part, by the requirement of NFAT phosphorylation.
The sites of NFAT phosphorylation that contribute to the
interaction with 14-3-3 correspond to PKA sites. Indeed, it is
likely that PKA is a physiologically relevant protein kinase
since dibutyryl cAMP increases NFAT binding to 14-3-3 in
calcium-stimulated cells (Fig. 5). However, the sites of PKA
phosphorylation may also be phosphorylated by other protein
kinases with similar substrate specificity, including calmodulin-
dependent protein kinases, PKB, and PKC. Thus, the regula-
tion of NFAT interaction with 14-3-3 may be a site of integra-
tion of multiple signaling pathways that ensures correct
responses to complex biological stimuli.
ACKNOWLEDGMENTS
We thank A. Altman, T. Hoey, Y.-C. Liu, R. Maurer, A. Rao, and
T. Soderling for providing reagents; T. Barrett and M. Sharma for
technical assistance; and K. Gemme for administrative assistance.
C.-W. Chow is an Arthritis Foundation fellow. This work was sup-
ported in part by grants CA65861 and CA72009 from the National
Cancer Institute. R.J.D. is an Investigator of the Howard Hughes
Medical Institute.
REFERENCES
1. Abbott, K. L., B. B. Friday, D. Thaloor, T. J. Murphy, and G. K. Pavlath.
1998. Activation and cellular localization of the cyclosporine A-sensitive
transcription factor NF-AT in skeletal muscle cells. Mol. Biol. Cell 9:2905–
2916.
2. Aitken, A. 1995. 14-3-3 proteins on the MAP. Trends Biochem. Sci. 20:95–97.
3. Aramburu, J., F. Garcia-Cozar, A. Raghavan, H. Okamura, A. Rao, and
P. G. Hogan. 1998. Selective inhibition of NFAT activation by a peptide
spanning the calcineurin targeting site of NFAT. Mol. Cell 1:627–637.
4. Beals, C. R., N. A. Clipstone, S. N. Ho, and G. R. Crabtree. 1997. Nuclear
localization of NF-ATc by a calcineurin-dependent, cyclosporin- sensitive
intramolecular interaction. Genes Dev. 11:824–834.
5. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree.
1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.
Science 275:1930–1934.
6. Bodor, J., and J. F. Habener. 1998. Role of transcriptional repressor ICER
in cyclic AMP-mediated attenuation of cytokine gene expression in human
thymocytes. J. Biol. Chem. 273:9544–9551.
7. Bonnefoy-Berard, N., Y. C. Liu, M. von Willebrand, A. Sung, C. Elly, T.
Mustelin, H. Yoshida, K. Ishizaka, and A. Altman. 1995. Inhibition of phos-
phatidylinositol 3-kinase activity by association with 14-3-3 proteins in T
cells. Proc. Natl. Acad. Sci. USA 92:10142–10146.
8. Boyle, W. J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping
and phosphoamino acid analysis by two-dimensional thin layer cellulose
plates. Methods Enzymol. 201:110–149.
9. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J.
Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes
cell survival by phosphorylating and inhibiting a Forkhead transcription
factor. Cell 96:857–868.
10. Chang, H. C., and G. M. Rubin. 1997. 14-3-3 epsilon positively regulates
Ras-mediated signaling in Drosophila. Genes Dev. 11:1132–1139.
11. Chin, E. R., E. N. Olson, J. A. Richardson, Q. Yang, C. Humphries, J. M.
Shelton, H. Wu, W. Zhu, R. Bassel-Duby, and R. S. Williams. 1998. A
calcineurin-dependent transcriptional pathway controls skeletal muscle fiber
type. Genes Dev. 12:2499–2509.
12. Chow, C.-W., M. Rincon, and R. J. Davis. 1999. Requirement of transcrip-
tion factor NFAT for interleukin 2 expression. Mol. Cell. Biol. 19:2300–2307.
13. Chow, C. W., M. Rincon, J. Cavanagh, M. Dickens, and R. J. Davis. 1997.
Nuclear accumulation of NFAT4 opposed by the JNK signal transduction
pathway. Science 278:1638–1641.
14. Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a
key signalling enzyme in T-lymphocyte activation. Nature 357:695–697.
15. Crabtree, G. R., and N. A. Clipstone. 1994. Signal transmission between the
plasma membrane and nucleus of T lymphocytes. Annu. Rev. Biochem.
63:1045–1083.
16. de la Pompa, J. L., L. A. Timmerman, H. Takimoto, H. Yoshida, A. J. Elia,
E. Samper, J. Potter, A. Wakeham, L. Marengere, B. L. Langille, G. R.
Crabtree, and T. W. Mak. 1998. Role of the NF-ATc transcription factor in
morphogenesis of cardiac valves and septum. Nature 392:182–186.
17. Du, X., J. E. Fox, and S. Pei. 1996. Identification of a binding sequence for
the 14-3-3 protein within the cytoplasmic domain of the adhesion receptor,
platelet glycoprotein Ib alpha. J. Biol. Chem. 271:7362–7367.
18. Durand, D. B., J.-P. Shaw, M. R. Bush, R. E. Repogla, R. Belagaje, and G. R.
Crabtree. 1988. Characterization of antigen receptor response elements
within the interleukin-2 enhancer. Mol. Cell. Biol. 8:1715–1724.
19. Fantl, W. J., A. J. Muslin, A. Kikuchi, J. A. Martin, A. M. MacNicol, R. W.
Gross, and L. T. Williams. 1994. Activation of Raf-1 by 14-3-3 proteins.
Nature 371:612–614.
20. Flanagan, W. M., B. Corthesy, R. J. Bram, and G. R. Crabtree. 1991. Nuclear
association of a T-cell transcription factor blocked by FK-506 and cyclo-
sporin A. Nature 352:803–807.
710 CHOW AND DAVIS MOL. CELL. BIOL.
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
21. Garcia-Cozar, F. J., H. Okamura, J. F. Aramburu, K. T. Y. Shaw, L. Pelle-
tier, R. Showalter, E. Villafranca, and A. Rao. 1998. Two-site interaction of
nuclear factor of activated T cells with activated calcineurin. J. Biol. Chem.
273:23877–23883.
22. Haraguchi, S., R. A. Good, and N. K. Day. 1995. Immunosuppressive retro-
viral peptides: cAMP and cytokine patterns. Immunol. Today 16:595–603.
23. Ho, A. M., J. Jain, A. Rao, and P. G. Hogan. 1994. Expression of the
transcription factor NFATp in a neuronal cell line and in the murine nervous
system. J. Biol. Chem. 269:28181–28186.
24. Ho, I. C., M. R. Hodge, J. W. Rooney, and L. H. Glimcher. 1996. The
proto-oncogene c-maf is responsible for tissue-specific expression of inter-
leukin-4. Cell 85:973–983.
25. Ho, S. N., D. J. Thomas, L. A. Timmerman, X. Li, U. Francke, and G. R.
Crabtree. 1995. NFATc3, a lymphoid-specific NFATc family member that is
calcium-regulated and exhibits distinct DNA binding specificity. J. Biol.
Chem. 270:19898–19907.
26. Hodge, M. R., A. M. Ranger, C. F. de la Brousse, T. Hoey, M. J. Grusby, and
L. H. Glimcher. 1996. Hyperproliferation and dysregulation of IL-4 expres-
sion in NF-ATp-deficient mice. Immunity 4:397–405.
27. Hoey, T., Y. L. Sun, K. Williamson, and X. Xu. 1995. Isolation of two new
members of the NF-AT gene family and functional characterization of the
NF-AT proteins. Immunity 2:461–472.
28. Hsueh, Y.-P., and M.-Z. Lai. 1995. c-Jun N-terminal kinase but not mitogen-
activated protein kinase is sensitive to cAMP inhibition in T lymphocytes.
J. Biol. Chem. 270:18094–18098.
29. Jain, J., P. G. McCaffrey, Z. Miner, T. K. Kerppola, J. N. Lambert, G. L.
Verdine, T. Curran, and A. Rao. 1993. The T-cell transcription factor
NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature
365:352–355.
30. Kaffman, A., N. M. Rank, E. M. O’Neill, L. S. Huang, and E. K. O’Shea.
1998. The receptor Msn5 exports the phosphorylated transcription factor
Pho4 out of the nucleus. Nature 396:482–486.
31. Kammer, G. M. 1988. The adenylate cyclase-cAMP-protein kinase A path-
way and regulation of the immune response. Immunol. Today 9:222–229.
32. Kehlenbach, R. H., A. Dickmanns, and L. Gerace. 1998. Nucleocytoplasmic
shuttling factors including Ran and CRM1 mediate nuclear export of NFAT
in vitro. J. Cell Biol. 141:863–874.
33. Klemm, J. D., C. R. Beals, and G. R. Crabtree. 1997. Rapid targeting of
nuclear proteins to the cytoplasm. Curr. Biol. 7:638–644.
34. Kockel, L., G. Vorbruggen, H. Jackle, M. Mlodzik, and D. Bohmann. 1997.
Requirement for Drosophila 14-3-3 zeta in Raf-dependent photoreceptor
development. Genes Dev. 11:1140–1147.
35. Komeili, A., and E. K. O’Shea. 1999. Roles of phosphorylation sites in
regulating activity of the transcription factor Pho4. Science 284:977–980.
36. Ku, N. O., J. Liao, and M. B. Omary. 1998. Phosphorylation of human
keratin 18 serine 33 regulates binding to 14-3-3 proteins. EMBO J. 17:1892–
1906.
37. Latinis, K. M., L. A. Norian, S. L. Eliason, and G. A. Koretzky. 1997. Two
NFAT transcription factor binding sites participate in the regulation of
CD95 (Fas) ligand expression in activated human T cells. J. Biol. Chem.
272:31427–31434.
38. Li, B., C. Tournier, R. J. Davis, and R. A. Flavell. 1999. Regulation of IL-4
expression by the transcription factor JunB during T helper cell differenti-
ation. EMBO J. 18:420–432.
39. Li, L., C. Yee, and J. A. Beavo. 1999. CD3- and CD28-dependent induction
of PDE7 required for T cell activation. Science 283:848–851.
40. Liu, D., J. Bienkowska, C. Petosa, R. J. Collier, H. Fu, and R. Liddington.
1995. Crystal structure of the zeta isoform of the 14-3-3 protein. Nature
376:191–194.
41. Liu, Y. C., C. Elly, H. Yoshida, N. Bonnefoy-Berard, and A. Altman. 1996.
Activation-modulated association of 14-3-3 proteins with Cbl in T cells.
J. Biol. Chem. 271:14591–14595.
42. Liu, Y. C., Y. Liu, C. Elly, H. Yoshida, S. Lipkowitz, and A. Altman. 1997.
Serine phosphorylation of Cbl induced by phorbol ester enhances its asso-
ciation with 14-3-3 proteins in T cells via a novel serine-rich 14- 3-3-binding
motif. J. Biol. Chem. 272:9979–9985.
43. Lopez-Girona, A., B. Furnari, O. Mondesert, and P. Russell. 1999. Nuclear
localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein.
Nature 397:172–175.
44. Luo, C., K. T. Shaw, A. Raghavan, J. Aramburu, F. Garcia-Cozar, B. A.
Perrino, P. G. Hogan, and A. Rao. 1996. Interaction of calcineurin with a
domain of the transcription factor NFAT1 that controls nuclear import.
Proc. Natl. Acad. Sci. USA 93:8907–8912.
45. Masuda, E. S., Y. Naito, H. Tokumitsu, D. Campbell, F. Saito, C. Hannum,
K. Arai, and N. Arai. 1995. NFATx, a novel member of the nuclear factor of
activated T cells family that is expressed predominantly in the thymus. Mol.
Cell. Biol. 15:2697–2706.
46. Maurer, R. A. 1989. Both isoforms of the cAMP-dependent protein kinase
catalytic subunit can activate transcription of the prolactin gene. J. Biol.
Chem. 264:6870–6873.
47. McCaffrey, P. G., A. E. Goldfeld, and A. Rao. 1994. The role of NFATp in
cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription.
J. Biol. Chem. 269:30445–30450.
48. McCaffrey, P. G., C. Luo, T. K. Kerppola, J. Jain, T. M. Badalian, A. M. Ho,
E. Burgeon, W. S. Lane, J. N. Lambert, T. Curran, et al. 1993. Isolation of
the cyclosporin-sensitive T cell transcription factor NFATp. Science 262:
750–754.
49. Meller, N., Y. C. Liu, T. L. Collins, N. Bonnefoy-Berard, G. Baier, N. Isakov,
and A. Altman. 1996. Direct interaction between protein kinase Cu (PKCu)
and 14-3-3t in T cells: 14-3-3 overexpression results in inhibition of PKCu
translocation and function. Mol. Cell. Biol. 16:5782–5791.
50. Molkentin, J. D., J. R. Lu, C. L. Antos, B. Markham, J. Richardson, J.
Robbins, S. R. Grant, and E. N. Olson. 1998. A calcineurin-dependent
transcriptional pathway for cardiac hypertrophy. Cell 93:215–228.
51. Moore, B. W., and V. J. Perez (ed.). 1967. Specific acidic proteins of the
nervous system. Prentice-Hall, Englewood Cliffs, N.J.
52. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990.
Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-
mediated activation: role of cAMP in T cell proliferation. J. Exp. Med.
172:95–103.
53. Muslin, A. J., J. W. Tanner, P. M. Allen, and A. S. Shaw. 1996. Interaction
of 14-3-3 with signaling proteins is mediated by the recognition of phospho-
serine. Cell 84:889–897.
54. Neumann, M., T. Grieshammer, S. Chuvpilo, B. Kneitz, M. Lohoff, A.
Schimpl, B. R. Franza, Jr., and E. Serfling. 1995. RelA/p65 is a molecular
target for the immunosuppressive action of protein kinase A. EMBO J.
14:1991–2004.
55. Nielsen, P. J. 1991. Primary structure of a human protein kinase regulator
protein. Biochim. Biophys. Acta 1088:425–428.
56. Northrop, J. P., S. N. Ho, L. Chen, D. J. Thomas, L. A. Timmerman, G. P.
Nolan, A. Admon, and G. R. Crabtree. 1994. NF-AT components define a
family of transcription factors targeted in T-cell activation. Nature 369:497–
502.
57. Oukka, M., I. C. Ho, F. C. de la Brousse, T. Hoey, M. J. Grusby, and L. H.
Glimcher. 1998. The transcription factor NFAT4 is involved in the genera-
tion and survival of T cells. Immunity 9:295–304.
58. Patel, M. D., L. E. Samelson, and R. D. Klausner. 1987. Multiple kinases and
signal transduction: phosphorylation of the T cell antigen receptor complex.
J. Biol. Chem. 262:5831–5838.
59. Peng, C. Y., P. R. Graves, R. S. Thoma, Z. Wu, A. S. Shaw, and H. Piwnica-
Worms. 1997. Mitotic and G2 checkpoint control: regulation of 14-3-3 pro-
tein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501–
1505.
60. Perrino, B. A., Y. L. Fong, D. A. Bricky, Y. Saitoh, Y. Ushio, K. Fukunaga,
E. Miyamoto, and T. R. Soderling. 1992. Characterization of the phosphatase
activity of a baculovirus-expressed calcineurin A isoform. J. Biol. Chem.
267:15965–15969.
61. Ranger, A. M., M. J. Grusby, M. R. Hodge, E. M. Gravallese, F. C. de la
Brousse, T. Hoey, C. Mickanin, H. S. Baldwin, and L. H. Glimcher. 1998.
The transcription factor NF-ATc is essential for cardiac valve formation.
Nature 392:186–190.
62. Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT
family: regulation and function. Annu. Rev. Immunol. 15:707–747.
63. Reuther, G. W., and A. M. Pendergast. 1996. The roles of 14-3-3 proteins in
signal transduction. Vitam. Horm. 52:149–175.
64. Rittinger, K., J. Budman, J. Xu, S. Volinia, L. C. Cantley, S. J. Smerdon, S. J.
Gamblin, and M. B. Yaffe. 1999. Structural analysis of 14-3-3 phosphopep-
tide complexes identifies a dual role for the nuclear export signal of 14-3-3 in
ligand binding. Mol. Cell 4:1–20.
65. Roy, S., R. A. McPherson, A. Apolloni, J. Yan, A. Lane, J. Clyde-Smith, and
J. F. Hancock. 1998. 14-3-3 facilitates Ras-dependent Raf-1 activation in
vitro and in vivo. Mol. Cell. Biol. 18:3947–3955.
66. Ruhlmann, A., and A. Nordheim. 1997. Effects of the immunosuppressive
drugs CsA and FK506 on intracellular signalling and gene regulation. Im-
munobiology 198:192–206.
67. Shaw, J. P., P. J. Utz, D. B. Durand, J. J. Toole, E. A. Emmel, and G. R.
Crabtree. 1988. Identification of a putative regulator of early T cell activation
genes. Science 241:202–205.
68. Shibasaki, F., E. R. Price, D. Milan, and F. McKeon. 1996. Role of kinases
and phosphatase calcineurin in the nuclear shuttling of transcription factor
NFAT4. Nature 382:370–373.
69. Siegel, M. D., D. H. Zhang, P. Ray, and A. Ray. 1995. Activation of the
interleukin-5 promoter by cAMP in murine EL-4 cells requires the GATA-3
and CLE0 elements. J. Biol. Chem. 270:24548–24555.
70. Szabo, S. J., J. S. Gold, T. L. Murphy, and K. M. Murphy. 1993. Identifica-
tion of cis-acting regulatory elements controlling interleukin-4 gene expres-
sion in T cells: roles for NF-Y and NF-ATc. Mol. Cell. Biol. 13:4793–4805.
71. Thorson, J. A., L. W. Yu, A. L. Hsu, N. Y. Shih, P. R. Graves, J. W. Tanner,
P. M. Allen, H. Piwnica-Worms, and A. S. Shaw. 1998. 14-3-3 proteins are
required for maintenance of Raf-1 phosphorylation and kinase activity. Mol.
Cell. Biol. 18:5229–5238.
72. Timmerman, L. A., N. A. Clipstone, S. N. Ho, J. P. Northrop, and G. R.
Crabtree. 1996. Rapid shuttling of NF-AT in discrimination of Ca21 signals
VOL. 20, 2000 NFAT INTERACTION WITH 14-3-3 711
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
and immunosuppression. Nature 383:837–840.
73. Tsuruta, L., H. J. Lee, E. S. Masuda, N. Koyano-Nakagawa, N. Arai, K. Arai,
and T. Yokota. 1995. Cyclic AMP inhibits expression of the IL-2 gene
through the nuclear factor of activated T cells (NF-AT) site, and transfection
of NF-AT cDNAs abrogates the sensitivity of EL-4 cells to cyclic AMP. J.
Immunol. 154:5255–5264.
74. Tzivion, G., Z. Luo, and J. Avruch. 1998. A dimeric 14-3-3 protein is an
essential cofactor for Raf kinase activity. Nature 394:88–92.
75. Uotila, P. 1996. The role of cyclic AMP and oxygen intermediates in the
inhibition of cellular immunity in cancer. Cancer Immunol. Immunother.
43:1–9.
76. Wartmann, M., and R. Davis. 1994. The native structure of the activated Raf
protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem.
269:6695–6701.
77. Xanthoudakis, S., J. P. Viola, K. T. Shaw, C. Luo, J. D. Wallace, P. T. Bozza,
D. C. Luk, T. Curran, and A. Rao. 1996. An enhanced immune response in
mice lacking the transcription factor NFAT1. Science 272:892–895.
78. Xiao, B., S. J. Smerdon, D. H. Jones, G. G. Dodson, Y. Soneji, A. Aitken, and
S. J. Gamblin. 1995. Structure of a 14-3-3 protein and implications for
coordination of multiple signalling pathways. Nature 376:188–191.
79. Yaffe, M. B., K. Rittinger, S. Volinia, P. R. Caron, A. Aitken, H. Leffers, S. J.
Gamblin, S. J. Smerdon, and L. C. Cantley. 1997. The structural basis for
14-3-3:phosphopeptide binding specificity. Cell 91:961–971.
80. Zha, J., H. Harada, E. Yang, J. Jockel, and S. J. Korsmeyer. 1996. Serine
phosphorylation of death agonist BAD in response to survival factor results
in binding to 14-3-3 not BCL-X(L). Cell 87:619–628.
81. Zhang, S. H., R. Kobayashi, P. R. Graves, H. Piwnica-Worms, and N. K.
Tonks. 1997. Serine phosphorylation-dependent association of the band 4.1-
related protein-tyrosine phosphatase PTPH1 with 14-3-3beta protein. J. Biol.
Chem. 272:27281–27287.
82. Zhu, J., and F. McKeon. 1999. NF-AT activation requires suppression of
Crm1-dependent export by calcineurin. Nature 398:256–260.
83. Zhu, J., F. Shibasaki, R. Price, J. C. Guillemot, T. Yano, V. Dotsch, G.
Wagner, P. Ferrara, and F. McKeon. 1998. Intramolecular masking of nu-
clear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 93:851–
861.
712 CHOW AND DAVIS MOL. CELL. BIOL.
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
